Answers are grounded in this paper and cite their sources.
CD4(+)CD25(+)CD127(lo)CD45RA(+) Tregs may be the most appropriate population from which to expand Tregs for autologous Treg therapy for CD, paving the way for future clinical trials.
No takes yet. Share an insight, caveat, or question.
Canavan et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: